---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-244642"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:49:47.105352+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Tarsus Pharmaceuticals appoints Rosemary A. Crane to Board; creates Science and Technology Committee

## Summary
- Crane appointed to Board effective Aug 11, 2021; will chair Audit and new Science and Technology Committees.
- Jason Tester resigned from Board and Audit Committee on Aug 10, 2021; no disagreement with Company.
- Wendy Yarno appointed Chair of Compensation Committee; Andrew Goldberg moved to Science and Technology Committee.
- Crane receives initial option for 20,000 shares under non-employee director compensation policy.
- Crane brings 30+ years pharma experience, including former CEO of MELA Sciences and Epocrates, senior roles at J&J and Bristol Myers Squibb.

## SEC filing metadata
- accession: 0001193125-21-244642
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000119312521244642/0001193125-21-244642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000119312521244642/d166164d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-244642
- JSON: https://secwatch.observer/filing/0001193125-21-244642.json
- Plain text: https://secwatch.observer/filing/0001193125-21-244642.txt

## Key facts
- Executive change
  Rosemary A. Crane was appointed as Chair of the Science and Technology Committee at Tarsus Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chair of the Science and Technology Committee
  source text: The Board appointed Ms. Crane to serve as Chair of the Science and Technology Committee
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000119312521244642/0001193125-21-244642-index.htm
- Executive change
  Rosemary A. Crane was appointed as Director at Tarsus Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Rosemary A. Crane to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000119312521244642/0001193125-21-244642-index.htm
- Executive change
  Rosemary A. Crane was appointed as Chair of the Audit Committee at Tarsus Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chair of the Audit Committee
  source text: the Board appointed Ms. Crane to serve as Chair of the Audit Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000119312521244642/0001193125-21-244642-index.htm
- Executive change
  Jason Tester resigned as Director at Tarsus Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: Jason Tester, a member of the Company's Board and Chair of the Audit Committee of the Board, resigned from the Board and the Audit Committee of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000119312521244642/0001193125-21-244642-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.